Identification
- Summary
Tromethamine is a proton acceptor used for the prevention and correction of metabolic acidosis associated with various clinical conditions, such as cardiac bypass surgery.
- Generic Name
- Tromethamine
- DrugBank Accession Number
- DB03754
- Background
An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Tromethamine (DB03754)
- Weight
- Average: 121.135
Monoisotopic: 121.073893223 - Chemical Formula
- C4H11NO3
- Synonyms
- 1,1,1-tris(hydroxymethyl)methanamine
- 2-Amino-2-(hydroxymethyl)-1,3-propanediol
- aminotris(hydroxymethyl)methane
- THAM
- Tris
- Tris(hydroxymethyl)aminomethane
- Trometamol
- Tromethamine
- External IDs
- NSC-6365
Pharmacology
- Indication
For the prevention and correction of metabolic acidosis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UAmyloid beta A4 protein inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareFlecainide The serum concentration of Flecainide can be increased when it is combined with Tromethamine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Tham Injection, solution 3.6 g/100mL Intravenous Hospira, Inc. 2020-06-24 Not applicable US 
Tham Solution 36mg/ml Solution 36 mg / mL Intravenous Hospira Healthcare Ulc 1972-12-31 2018-10-03 Canada 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Sooryehan Hyo Fermented Sun Block Tromethamine (2.63 mL/100mL) + Amiloxate (1.6 mL/100mL) + Bemotrizinol (1 mL/100mL) + Diethylamino hydroxybenzoyl hexyl benzoate (1 mL/100mL) + Ensulizole (3.9 mL/100mL) + Octinoxate (7 mL/100mL) + Titanium dioxide (2.52 mL/100mL) Cream Topical Lg Household & Health Care Ltd. 2011-09-27 Not applicable US
Categories
- ATC Codes
- B05XX02 — Trometamol
- B05XX — Other i.v. solution additives
- B05X — I.V. SOLUTION ADDITIVES
- B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- Drug Categories
- Alcohols
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Buffers
- Compounds used in a research, industrial, or household setting
- Excipients
- Glycols
- I.V. Solution Additives
- i.v. Solutions
- Laboratory Chemicals
- Pharmaceutic Aids
- Pharmaceutical Preparations
- Pharmaceutical Vehicles
- Propylene Glycols
- Solutions Affecting the Electrolyte Balance
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Amines
- Direct Parent
- 1,2-aminoalcohols
- Alternative Parents
- Primary alcohols / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
- Substituents
- 1,2-aminoalcohol / Alcohol / Aliphatic acyclic compound / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Organopnictogen compound / Primary alcohol / Primary aliphatic amine / Primary amine
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- primary amino compound, triol (CHEBI:9754) / a small molecule (TRIS)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 023C2WHX2V
- CAS number
- 77-86-1
- InChI Key
- LENZDBCJOHFCAS-UHFFFAOYSA-N
- InChI
- InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2
- IUPAC Name
- 2-amino-2-(hydroxymethyl)propane-1,3-diol
- SMILES
- NC(CO)(CO)CO
References
- Synthesis Reference
Jean Bourguignon, Marcel-Xavier Sion, Michel Moreau, "Preparation of tris(hydroxymethyl)aminomethane." U.S. Patent US4233245, issued August, 1959.
US4233245- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0240288
- KEGG Drug
- D00396
- KEGG Compound
- C07182
- PubChem Compound
- 6503
- PubChem Substance
- 46506027
- ChemSpider
- 6257
- 10865
- ChEBI
- 9754
- ChEMBL
- CHEMBL1200391
- ZINC
- ZINC000000896695
- PDBe Ligand
- TRS
- Wikipedia
- Tris
- FDA label
- Download (88.7 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Cream Topical Injection, solution Intravenous 3.6 g/100mL Solution Intravenous 36 mg / mL Injection, solution Intravenous; Parenteral 3.6 % Solution Intravenous 3.6 % - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 695.0 mg/mL ALOGPS logP -2.1 ALOGPS logP -2.7 Chemaxon logS 0.76 ALOGPS pKa (Strongest Acidic) 14.16 Chemaxon pKa (Strongest Basic) 8.95 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 86.71 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 28.36 m3·mol-1 Chemaxon Polarizability 12.02 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.52 Blood Brain Barrier - 0.6989 Caco-2 permeable - 0.6613 P-glycoprotein substrate Non-substrate 0.6664 P-glycoprotein inhibitor I Non-inhibitor 0.9749 P-glycoprotein inhibitor II Non-inhibitor 0.9671 Renal organic cation transporter Non-inhibitor 0.9239 CYP450 2C9 substrate Non-substrate 0.8432 CYP450 2D6 substrate Non-substrate 0.8337 CYP450 3A4 substrate Non-substrate 0.8096 CYP450 1A2 substrate Non-inhibitor 0.8179 CYP450 2C9 inhibitor Non-inhibitor 0.9095 CYP450 2D6 inhibitor Non-inhibitor 0.9027 CYP450 2C19 inhibitor Non-inhibitor 0.895 CYP450 3A4 inhibitor Non-inhibitor 0.9568 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9686 Ames test Non AMES toxic 0.9257 Carcinogenicity Non-carcinogens 0.7844 Biodegradation Ready biodegradable 0.582 Rat acute toxicity 1.5129 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9739 hERG inhibition (predictor II) Non-inhibitor 0.9664
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-QQ , positive LC-MS/MS splash10-00di-0900000000-53da6b0f35ab1e8e8a57 LC-MS/MS Spectrum - LC-ESI-QQ , positive LC-MS/MS splash10-0pi0-7900000000-244b89c0e2e656701b1d LC-MS/MS Spectrum - LC-ESI-QQ , positive LC-MS/MS splash10-0a4i-9000000000-a468801012da982d3bac LC-MS/MS Spectrum - LC-ESI-QQ , positive LC-MS/MS splash10-0a4i-9000000000-eb66f99d48d2027e0fb2 LC-MS/MS Spectrum - LC-ESI-QQ , positive LC-MS/MS splash10-0a4i-9000000000-2983a91b4350760fab44
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Transition metal ion binding
- Specific Function
- Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and tra...
- Gene Name
- APP
- Uniprot ID
- P05067
- Uniprot Name
- Amyloid beta A4 protein
- Molecular Weight
- 86942.715 Da
References
- Arispe N, Rojas E, Pollard HB: Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):567-71. doi: 10.1073/pnas.90.2.567. [Article]
Drug created at June 13, 2005 13:24 / Updated at December 05, 2023 12:31